Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor

Journal of Cystic Fibrosis

Volumn 16, Issue 1, 2017, Pages 41-44

  Fidler, Meredith C ^a   Beusmans, Jack ^a   Panorchan, Paul ^a   Van Goor, Fredrick ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cystic fibrosis; FEV1; Ivacaftor; Sweat chloride

Indexed keywords

CHLORIDE; IVACAFTOR; AMINOPHENOL DERIVATIVE; BIOLOGICAL MARKER; CHLORIDE CHANNEL STIMULATING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; QUINOLONE DERIVATIVE;

ARTICLE; CLINICAL EVALUATION; CLINICAL PRACTICE; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG FUNCTION; LUNG PARENCHYMA; MONOTHERAPY; SWEAT; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; MUTATION; PREDICTIVE VALUE; TREATMENT OUTCOME;

AMINOPHENOLS; BIOMARKERS; CHLORIDE CHANNEL AGONISTS; CHLORIDES; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FORCED EXPIRATORY VOLUME; HUMANS; MUTATION; PREDICTIVE VALUE OF TESTS; QUINOLONES; SWEAT; TREATMENT OUTCOME;

EID: 85008937033     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2016.10.002     Document Type: Article

References (17)

1. [1] Kerem, B., Rommens, J.M., Buchanan, J.A., Markiewicz, D., Cox, T.K., Chakravarti, A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 245 (1989), 1073–1080.
2. [2] Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245 (1989), 1066–1073.
3. [3] Rowe, S.M., Miller, S., Sorscher, E.J., Cystic fibrosis. N Engl J Med 352 (2005), 1992–2001.
4. [4] Ramsey, B.W., Davies, J., McElvaney, N.G., Tullis, E., Bell, S.C., Drevinek, P., et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365 (2011), 1663–1672.
5. [5] Davies, J.C., Wainwright, C.E., Canny, G.J., Chilvers, M.A., Howenstine, M.S., Munck, A., et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. Am J Respir Crit Care Med 187 (2013), 1219–1225.
6. [6] Flume, P.A., Liou, T.G., Borowitz, D.S., Li, H., Yen, K., Ordonez, C.L., et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 142 (2012), 718–724.
7. [7] Moss, R.B., Flume, P.A., Elborn, J.S., Cooke, J., Rowe, S.M., McColley, S.A., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. Lancet Respir Med 3 (2015), 524–533.
8. [8] De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G., et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros 13 (2014), 674–680.
9. [9] Accurso, F.J., Van Goor, F., Zha, J., Stone, A.J., Dong, Q., Ordonez, C.L., et al. Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. J Cyst Fibros 13 (2014), 139–147.
10. [10] Accurso, F.J., Rowe, S.M., Clancy, J.P., Boyle, M.P., Dunitz, J.M., Durie, P.R., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363 (2010), 1991–2003.
11. [11] Seliger, V.I., Rodman, D., Van Goor, F., Schmelz, A., Mueller, P., The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 12 (2013), 706–713.
12. [12] Durmowicz, A.G., Witzmann, K.A., Rosebraugh, C.J., Chowdhury, B.A., Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 143 (2013), 14–18.
13. [13] Yu, H., Burton, B., Huang, C.J., Worley, J., Cao, D., Johnson, J.P. Jr., et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11 (2012), 237–245.
14. 1 greater than or equal to 40 percent of predicted, N-OF-1 study. Pediatr Pulmonol, 49(Suppl 38), 2014.
15. [15] Kirk, J.M., Keston, M., McIntosh, I., al Essa, S., Variation of sweat sodium and chloride with age in cystic fibrosis and normal populations: further investigations in equivocal cases. Ann Clin Biochem 29 (1992), 145–152.
16. [16] Collaco, J.M., Blackman, S.M., Raraigh, K.S., Corvol, H., Rommens, J.M., Pace, R.G., et al. Sources of variation in sweat chloride measurements in cystic fibrosis. Am J Respir Crit Care Med, 2016 Jun 3 [Epub ahead of print].
17. [17] Barry, P.J., Jones, A.M., Webb, A.K., Horsley, A.R., Sweat chloride is not a useful marker of clinical response to ivacaftor. Thorax 69 (2014), 586–587.